135 related articles for article (PubMed ID: 36863566)
41. Impact of thromboprophylaxis across the US acute care setting.
Huang W; Anderson FA; Rushton-Smith SK; Cohen AT
PLoS One; 2015; 10(3):e0121429. PubMed ID: 25816146
[TBL] [Abstract][Full Text] [Related]
42. Defining high risk: cost-effectiveness of extended-duration thromboprophylaxis following major oncologic abdominal surgery.
Iannuzzi JC; Rickles AS; Kelly KN; Fleming FJ; Dolan JG; Monson JR; Noyes K
J Gastrointest Surg; 2014 Jan; 18(1):60-8. PubMed ID: 24101450
[TBL] [Abstract][Full Text] [Related]
43. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
[TBL] [Abstract][Full Text] [Related]
44. Postoperative venous thromboembolism risk stratification in patients with uterine cancer.
Wagner VM; Piver RN; Levine MD; Backes FJ; Chambers LJ; Cohn DE; Copeland LJ; Cosgrove CM; Nagel CI; O'Malley DM; Bixel KL
Am J Obstet Gynecol; 2023 May; 228(5):555.e1-555.e8. PubMed ID: 36574873
[TBL] [Abstract][Full Text] [Related]
45. Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China.
Yan X; Gu X; Xu Z; Lin H; Wu B
Adv Ther; 2017 Feb; 34(2):466-480. PubMed ID: 28000167
[TBL] [Abstract][Full Text] [Related]
46. Chemoprophylaxis for venous thromboembolism in otolaryngology.
Bahl V; Shuman AG; Hu HM; Jackson CR; Pannucci CJ; Alaniz C; Chepeha DB; Bradford CR
JAMA Otolaryngol Head Neck Surg; 2014 Nov; 140(11):999-1005. PubMed ID: 25275427
[TBL] [Abstract][Full Text] [Related]
47. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
[TBL] [Abstract][Full Text] [Related]
48. Screening and prevention of venous thromboembolism in critically ill patients: a decision analysis and economic evaluation.
Sud S; Mittmann N; Cook DJ; Geerts W; Chan B; Dodek P; Gould MK; Guyatt G; Arabi Y; Fowler RA; ;
Am J Respir Crit Care Med; 2011 Dec; 184(11):1289-98. PubMed ID: 21868500
[TBL] [Abstract][Full Text] [Related]
49. Cost-effectiveness of prophylactic low molecular weight heparin in pregnant women with a prior history of venous thromboembolism.
Johnston JA; Brill-Edwards P; Ginsberg JS; Pauker SG; Eckman MH
Am J Med; 2005 May; 118(5):503-14. PubMed ID: 15866253
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients.
Wang TF; Milligan PE; Wong CA; Deal EN; Thoelke MS; Gage BF
Thromb Haemost; 2014 Jan; 111(1):88-93. PubMed ID: 24136071
[TBL] [Abstract][Full Text] [Related]
51. A retrospective review of the use of thromboprophylaxis in patients who subsequently developed a venous thromboembolism after discharge from hospital.
Wiseman DN; Harrison J
N Z Med J; 2010 Feb; 123(1309):37-49. PubMed ID: 20186241
[TBL] [Abstract][Full Text] [Related]
52. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia.
Rank CU; Lynggaard LS; Als-Nielsen B; Stock W; Toft N; Nielsen OJ; Frandsen TL; Tuckuviene R; Schmiegelow K
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013399. PubMed ID: 33038027
[TBL] [Abstract][Full Text] [Related]
53. Is thromboprophylaxis cost effective in ovarian hyperstimulation syndrome: A systematic review and cost analysis.
Wormer KC; Jangda AA; El Sayed FA; Stewart KI; Mumford SL; Segars JH
Eur J Obstet Gynecol Reprod Biol; 2018 May; 224():117-124. PubMed ID: 29602141
[TBL] [Abstract][Full Text] [Related]
54. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
McCullagh L; Tilson L; Walsh C; Barry M
Pharmacoeconomics; 2009; 27(10):829-46. PubMed ID: 19803538
[TBL] [Abstract][Full Text] [Related]
55. Extended thromboprophylaxis in the acutely ill medical patient after hospitalization - a paradigm shift in post-discharge thromboprophylaxis.
Mahan CE; Burnett AE; Fletcher ML; Spyropoulos AC
Hosp Pract (1995); 2018 Feb; 46(1):5-15. PubMed ID: 29171776
[TBL] [Abstract][Full Text] [Related]
56. Venous Thromboembolism Risk and Thromboprophylaxis Assessment in Surgical Patients Based on Caprini Risk Assessment Model.
Tadesse TA; Kedir HM; Fentie AM; Abiye AA
Risk Manag Healthc Policy; 2020; 13():2545-2552. PubMed ID: 33204195
[TBL] [Abstract][Full Text] [Related]
57. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients.
McGarry LJ; Thompson D; Weinstein MC; Goldhaber SZ
Am J Manag Care; 2004 Sep; 10(9):632-42. PubMed ID: 15515996
[TBL] [Abstract][Full Text] [Related]
58. The effectiveness of graduated compression stockings for prevention of venous thromboembolism in orthopedic and abdominal surgery patients requiring extended pharmacologic thromboprophylaxis.
Milinis K; Shalhoub J; Coupland AP; Salciccioli JD; Thapar A; Davies AH
J Vasc Surg Venous Lymphat Disord; 2018 Nov; 6(6):766-777.e2. PubMed ID: 30126797
[TBL] [Abstract][Full Text] [Related]
59. Real-World Comparative Effectiveness and Cost Comparison of Thromboprophylactic Use of Enoxaparin versus Unfractionated Heparin in 376,858 Medically Ill Hospitalized US Patients.
Veeranki SP; Xiao Z; Levorsen A; Sinha M; Shah BR
Am J Cardiovasc Drugs; 2021 Jul; 21(4):443-452. PubMed ID: 33313988
[TBL] [Abstract][Full Text] [Related]
60. To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients.
Spyropoulos AC
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):506-514. PubMed ID: 36485109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
